| Dr Robert Bruce Bracken, MD | |
|
222 Piedmont Ave, Ste. 7000, Cincinnati, OH 45219-4231 | |
| (513) 475-8787 | |
| (513) 475-7239 |
| Full Name | Dr Robert Bruce Bracken |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 222 Piedmont Ave, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386612398 | NPI | - | NPPES |
| 0505395 | Medicaid | OH | |
| 64780364 | Medicaid | KY | |
| 100328150 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 35-046750 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Bruce Bracken, MD 3200 Burnet Ave, 3 South, Credentialing, Cincinnati, OH 45229-3019 Ph: (513) 475-8787 | Dr Robert Bruce Bracken, MD 222 Piedmont Ave, Ste. 7000, Cincinnati, OH 45219-4231 Ph: (513) 475-8787 |
News Archive
Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).
A new online tool for calculating colorectal cancer risk in men and women age 50 or older was launched today, based on a new risk-assessment model developed by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health.
Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.
Scientists are one step closer to deciphering the molecular signaling process controlling innate immunity with the discovery that a molecule called IRAK1 regulates the expression of the anti-inflammatory cytokine IL-10. Because atherosclerosis patients often have elevated IL-10 levels, IRAK1 may be a viable target for developing therapeutics for atherosclerosis.
› Verified 5 days ago
Dr. Ayman Mahdy, Urology Medicare: Accepting Medicare Assignments Practice Location: 222 Piedmont Ave, Cincinnati, OH 45219 Phone: 513-475-8787 Fax: 513-475-7348 | |
Pramod P Reddy, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3333 Burnet Avenue, Ml 5037, Cincinnati, OH 45229 Phone: 513-636-4975 Fax: 866-213-7089 | |
Justin Cox, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2123 Auburn Ave, Cincinnati, OH 45219 Phone: 513-721-7373 Fax: 513-977-4253 | |
Brian Joseph Minnillo, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 4360 Ferguson Dr Ste 100, Cincinnati, OH 45245 Phone: 513-841-7750 Fax: 513-841-7751 | |
Philip J Buffington, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 4360 Ferguson Dr Ste 100, Cincinnati, OH 45245 Phone: 513-841-7750 Fax: 513-841-7751 | |
Richard H Keys, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2000 Joseph E Sanker Blvd, Cincinnati, OH 45212 Phone: 513-841-7400 Fax: 513-841-7402 | |
Marc J Pliskin, DO Urology Medicare: Accepting Medicare Assignments Practice Location: 3301 Mercy Health Blvd, Suite 525, Cincinnati, OH 45211 Phone: 513-841-7700 Fax: 513-841-7701 |